Needham Maintains Buy on Vir Biotechnology, Raises Price Target to $18
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $14 to $18.
Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $14 to $18.